X4 Pharmaceuticals (XFOR) Competitors

$4.00 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.00 +0.00 (+0.12%)

As of 06/12/2026 07:48 PM Eastern

XFOR vs. MBX, GLUE, KALV, IMCR, and AVBP

Should you buy X4 Pharmaceuticals stock or one of its competitors? MarketBeat compares X4 Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with X4 Pharmaceuticals include MBX Biosciences (MBX), Monte Rosa Therapeutics (GLUE), KalVista Pharmaceuticals (KALV), Immunocore (IMCR), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

How does X4 Pharmaceuticals compare to MBX Biosciences?

X4 Pharmaceuticals (NASDAQ:XFOR) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MBX Biosciences had 8 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 9 mentions for MBX Biosciences and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat MBX Biosciences' score of 0.40 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
X4 Pharmaceuticals	Very Positive
MBX Biosciences	Neutral

X4 Pharmaceuticals currently has a consensus price target of $9.38, suggesting a potential upside of 134.38%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 69.59%. Given X4 Pharmaceuticals' higher probable upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

X4 Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. MBX Biosciences' return on equity of -24.52% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
MBX Biosciences	N/A	-24.52%	-23.59%

X4 Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.75	-$79.20M	-$4.54	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Summary

MBX Biosciences beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Monte Rosa Therapeutics has higher revenue and earnings than X4 Pharmaceuticals. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A
X4 Pharmaceuticals	$35.11M	10.75	-$79.20M	-$4.54	N/A

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Monte Rosa Therapeutics' score of 1.21 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Monte Rosa Therapeutics	Positive
X4 Pharmaceuticals	Very Positive

Monte Rosa Therapeutics has a net margin of -302.69% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Monte Rosa Therapeutics' return on equity of -40.99% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Monte Rosa Therapeutics currently has a consensus price target of $32.50, suggesting a potential upside of 78.18%. X4 Pharmaceuticals has a consensus price target of $9.38, suggesting a potential upside of 134.38%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Monte Rosa Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats X4 Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, KalVista Pharmaceuticals had 7 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for KalVista Pharmaceuticals and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat KalVista Pharmaceuticals' score of 1.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
X4 Pharmaceuticals	Very Positive
KalVista Pharmaceuticals	Positive

X4 Pharmaceuticals currently has a consensus target price of $9.38, suggesting a potential upside of 134.38%. KalVista Pharmaceuticals has a consensus target price of $30.60, suggesting a potential upside of 13.33%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

X4 Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.75	-$79.20M	-$4.54	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

KalVista Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

X4 Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Summary

X4 Pharmaceuticals beats KalVista Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Immunocore?

Immunocore (NASDAQ:IMCR) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Immunocore has higher revenue and earnings than X4 Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.68	-$35.51M	-$0.55	N/A
X4 Pharmaceuticals	$35.11M	10.75	-$79.20M	-$4.54	N/A

Immunocore has a net margin of -6.68% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Immunocore's return on equity of -7.07% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

84.5% of Immunocore shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunocore presently has a consensus price target of $56.71, suggesting a potential upside of 95.84%. X4 Pharmaceuticals has a consensus price target of $9.38, suggesting a potential upside of 134.38%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, Immunocore had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for Immunocore and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Immunocore's score of 0.94 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunocore	Positive
X4 Pharmaceuticals	Very Positive

Summary

Immunocore beats X4 Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

X4 Pharmaceuticals (NASDAQ:XFOR) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, ArriVent BioPharma had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for ArriVent BioPharma and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.87 beat ArriVent BioPharma's score of 0.94 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
X4 Pharmaceuticals	Very Positive
ArriVent BioPharma	Positive

X4 Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.75	-$79.20M	-$4.54	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. ArriVent BioPharma's return on equity of -48.98% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
ArriVent BioPharma	N/A	-48.98%	-45.44%

X4 Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

X4 Pharmaceuticals currently has a consensus target price of $9.38, suggesting a potential upside of 134.38%. ArriVent BioPharma has a consensus target price of $43.38, suggesting a potential upside of 42.03%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

ArriVent BioPharma beats X4 Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$377.28M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-0.88	19.82	24.21	24.42
Price / Sales	10.75	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.88	8.32	10.66	6.83
Net Income	-$79.20M	$23.94M	$3.57B	$337.67M
7 Day Performance	7.82%	1.84%	0.58%	1.17%
1 Month Performance	1.52%	-0.04%	1.54%	3.16%
1 Year Performance	41.84%	44.82%	25.40%	30.58%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	2.8335 of 5 stars	$4.00 flat	$9.38 +134.4%	+41.8%	$377.28M	$35.11M	N/A	80	Positive News
MBX MBX Biosciences	2.6613 of 5 stars	$29.00 -4.2%	$60.22 +107.7%	N/A	$1.44B	N/A	N/A	N/A	Gap Up
GLUE Monte Rosa Therapeutics	2.4021 of 5 stars	$17.00 +3.8%	$32.50 +91.2%	+271.5%	$1.44B	$42.95M	N/A	90	Positive News Gap Down High Trading Volume
KALV KalVista Pharmaceuticals	3.1002 of 5 stars	$26.99 +0.1%	$30.60 +13.4%	N/A	$1.43B	$49.08M	N/A	100	Positive News Analyst Upgrade Short Interest Decrease
IMCR Immunocore	3.2599 of 5 stars	$27.79 -1.8%	$56.71 +104.1%	-16.5%	$1.43B	$400.02M	N/A	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. MBX, GLUE, KALV, IMCR, and AVBP

How does X4 Pharmaceuticals compare to MBX Biosciences?

Summary

How does X4 Pharmaceuticals compare to Monte Rosa Therapeutics?

Summary

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

Summary

How does X4 Pharmaceuticals compare to Immunocore?

Summary

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. MBX, GLUE, KALV, IMCR, and AVBP

How does X4 Pharmaceuticals compare to MBX Biosciences?

Do insiders and institutionals hold more shares of XFOR or MBX?

Does the media refer more to XFOR or MBX?

Do analysts recommend XFOR or MBX?

Which has more risk & volatility, XFOR or MBX?

Is XFOR or MBX more profitable?

Which has higher earnings and valuation, XFOR or MBX?

Summary

How does X4 Pharmaceuticals compare to Monte Rosa Therapeutics?

Which has better valuation and earnings, GLUE or XFOR?

Does the media favor GLUE or XFOR?

Is GLUE or XFOR more profitable?

Do insiders & institutionals hold more shares of GLUE or XFOR?

Do analysts recommend GLUE or XFOR?

Which has more volatility & risk, GLUE or XFOR?

Summary

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

Does the media refer more to XFOR or KALV?

Do analysts recommend XFOR or KALV?

Which has stronger valuation & earnings, XFOR or KALV?

Do institutionals and insiders hold more shares of XFOR or KALV?

Is XFOR or KALV more profitable?

Which has more risk and volatility, XFOR or KALV?

Summary

How does X4 Pharmaceuticals compare to Immunocore?

Which has better earnings and valuation, IMCR or XFOR?

Is IMCR or XFOR more profitable?

Do insiders and institutionals hold more shares of IMCR or XFOR?

Do analysts prefer IMCR or XFOR?

Which has more risk & volatility, IMCR or XFOR?

Does the media refer more to IMCR or XFOR?

Summary

How does X4 Pharmaceuticals compare to ArriVent BioPharma?

Does the media refer more to XFOR or AVBP?

Which has better valuation & earnings, XFOR or AVBP?

Is XFOR or AVBP more profitable?

Which has more volatility and risk, XFOR or AVBP?

Do insiders & institutionals hold more shares of XFOR or AVBP?

Do analysts rate XFOR or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools